01—Abstract
Summary
Summary of the 10-Q filed October 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher's Q3 2025 10-Q shows steady top-line momentum with third-quarter sales up 4.5% to $6.05 billiona and core sales up 3.0%, led by Biotechnology (+6.5% core) and Diagnostics (+3.5% core), while Life Sciences declined about 1% in core sales.
Diluted EPS rose to $1.27b from $1.12 in the prior-year quarter, and operating margin expanded to 19.1% from 16.5%, though the comparison is flattered by a $222 million impairment in Q3 2024. For the nine months, net earnings fell to $2.42 billion from $2.81 billion and diluted EPS to $3.37 from $3.80, driven mainly by $548 million of 2025 impairments (including a $432 million genomics trade name write-down in Life Sciences) and investment losses, partly offset by lower amortization and interest costs. Cash generation remained solid but softer: operating cash flow was $4.3 billion, down 8% year over year, and capital expenditures were $785 million.
Danaher returned substantial capital to shareholders, repurchasing about $3.1 billionc of stock in the nine months and paying $652 million in dividends, while also reducing treasury cash and cash equivalents to $1.5 billion. Total debt rose to about $16.9 billion, and management subsequently issued CHF 1.25 billion (about $1.6 billion) of Swiss franc bonds on October 10, 2025, which increases debt but adds liquidity for general corporate purposes including buybacks.
Management flagged headwinds that investors should weigh: a cautious bioprocessing equipment environment, weaker academic and government funding, China volume-based procurement pressure in Diagnostics, several hundred million dollars of incremental 2025 tariff costs (largely offset so far), a U.S. government shutdown beginning in October 2025, and ongoing securities litigation (Hawkins Action) where the outcome cannot be estimated. The effective tax rate outlook for the remainder of 2025 is about 17%d.
02—Key points
Key Highlights
- Q3 2025 sales rose 4.5% to $6,053 million (core sales +3.0%); nine-month sales rose 2.5% to $17,730 million (core +1.5%).
- Q3 diluted EPS of $1.27 vs. $1.12 a year earlier; operating margin expanded 260 bps to 19.1%, helped by lapping a $222 million Q3 2024 impairment.
- Nine-month net earnings fell 14% to $2,417 million, mainly due to $548 million of 2025 impairments (including a $432 million genomics trade name write-down) and $149 million of investment losses.
- Biotechnology was the growth engine, with nine-month core sales up 6.5% led by bioprocessing consumables; Life Sciences core sales declined 2.5% for the nine months amid weak academic and biotech funding.
- Operating cash flow was $4.3 billion (down 8%); capex was $785 million, and free cash flow remained healthy relative to dividends of $652 million.
- Shareholder returns remained significant: $3.1 billion of share repurchases year to date and a new 35 million-share authorization approved September 9, 2025.
- Debt rose to $16.9 billion; a CHF 1.25 billion (~$1.6 billion) Swiss bond issuance on October 10, 2025 was completed to fund general corporate purposes, including potential buybacks.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Danaher Corp kept $0.15.
- Revenue$6.05B100.0%
- Cost of revenue−$2.53B41.8%
- Gross profit$3.52B58.2%
- Operating costs−$2.37B39.1%
- Operating income$1.15B19.1%
- Interest, other & tax−$246.0M4.1%
- Net income$908.0M15.0%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 21, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $6.05B$5.80B | +4.4% |
| Cost of Revenue | $2.53B$2.40B | +5.5% |
| Gross Profit | $3.52B$3.40B | +3.6% |
| R&D Expenses | $378.00M$383.00M | −1.3% |
| SG&A Expenses | $1.99B$2.06B | −3.3% |
| Operating Income | $1.15B$958.00M | +20.5% |
| Net Income | $908.00M$818.00M | +11.0% |
| EPS (Basic) | $1.28$1.13 | +13.3% |
| EPS (Diluted) | $1.27$1.12 | +13.4% |
| Shares Outstanding (Basic) | 710.70M723.00M | −1.7% |
| Shares Outstanding (Diluted) | 713.70M729.40M | −2.2% |
05—Questions
Frequently Asked Questions
Why did Danaher's reported earnings decline year to date even though sales grew?
Nine-month net earnings fell to $2.42 billion from $2.81 billion because of $548 million of impairment charges in 2025 (versus $222 million in 2024), a swing to $149 million of investment losses from prior-year gains, and lower interest income from reduced cash balances. Operating profit fell 7% to $3.19 billion, though underlying core sales and margins were stable.
How healthy is Danaher's core growth outlook across its segments?
Biotechnology and Diagnostics are growing core sales (Biotechnology +6.5% for both periods; Diagnostics +3.5% in Q3 and +1.5% year to date), while Life Sciences is shrinking (-1.0% in Q3, -2.5% year to date). Management expects academic, government and bioprocessing equipment demand to remain cautious, and Diagnostics faces respiratory-test demand timing and China pricing pressure.
What is the impact of tariffs on Danaher's profitability?
Management expects incremental 2025 tariff costs of several hundred million dollars based on enacted tariffs. So far these have been largely offset through manufacturing footprint changes, supply chain adjustments, surcharges and productivity actions, but gross margin was pressured in Q3 by tariffs and currency. Additional tariffs or a failure to offset costs could materially affect results.
Is Danaher's balance sheet and liquidity position sound after recent borrowing and buybacks?
Cash fell to $1.5 billion from $2.1 billion, and total debt rose to about $16.9 billion from $16.0 billion. Liquidity is supported by a $5.0 billion revolving credit facility expiring in 2028, and the company states it was in compliance with all debt covenants. Most of the cash is held outside the U.S., and about $2.6 billion of commercial paper and 2026 euronotes are classified as long-term given refinancing intent.
What legal and contingent risks should investors monitor?
The Hawkins securities class action alleging misstatements about bioprocessing revenue survived in part a motion to dismiss on August 4, 2025, and related shareholder derivative suits are stayed pending that case. Management cannot reasonably estimate possible losses. Additional risks include the U.S. Supreme Court review of tariffs, the October 2025 U.S. government shutdown affecting NIH funding, and potential IRS challenges to self-insurance premium deferral for periods after 2018.
06—Continue